← Back

Wire · regulatory

Capricor reviewing operations as FDA rejects cell therapy

Published

21 November 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at seekingalpha.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

The U.S. FDA has declined to approve Capricor Therapeutics' cell therapy candidate Deramiocel for the second time in under two years, prompting the company to review its operating expenses.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 12 Nov 2026 and 21 Nov 2026.

◆ ◆ The Wire takeaway

You must brace for tougher FDA standards that just paused this therapy twice. This demand for clinical clarity will reshape how you approach funding and timelines in cell therapy.

◆ Coverage

7 sources · first reported 12 Nov 2026 · latest 21 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-rejectioncell-therapybiotechregulatory-delay